KOSPIBiotech & Pharma017180

Myungmoon Pharm

₩1,022▲ 0.49%2026-11-18 close
Market Cap
₩34.7B
Turnover
₩8,307,820
Volume
8.1K
Shares out.
34M
PER
—
PBR
0.4×
EPS
-₩373
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Myungmoon Pharm: Revenue Growth, Renewed Losses in 2026

Myungmoon Pharm grew revenue for three straight years through 2025 and returned to operating and controlling-shareholder profit, but operating losses in the second and third quarters of 2026 make the durability of that recovery the key question.

  1. 1

    Revenue in 2025 reached KRW 195.2 billion, up 4.7% from the prior year, and operating profit recovered to KRW 6.83 billion, up 254.4%.

  2. 2

    The Q3 2026 operating loss was KRW 8.3 billion, turning from a profit a year earlier, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 12.6 billion.

  3. 3

    Selling, general and administrative expenses are the main variable, with a Vegan News report putting Q3 2026 SG&A up 37.3% from a year earlier.

  4. 4

    An upgrade of injectable production capacity, a project of roughly KRW 20 billion, and securing EU GMP certification are presented as preconditions for overseas expansion.

  5. 5

    The debt ratio (total liabilities to total equity) stood at 160.8% at the end of 2025, and operating cash flow was -KRW 5.18 billion in 2023, -KRW 1.34 billion in 2024 and -KRW 1.7 billion in 2025.

02

Business structure

Myungmoon Pharm was founded in 1983 as a pharmaceutical company and holds consolidated subsidiaries. Its business is split into a medicines and biotech segment and a services segment.

The medicines segment manufactures and sells finished and raw-material drugs and distributes medicines, while the services segment runs academy operations and real estate development. Media reports said the share of product sales in total revenue rose from 67.3% in 2022 to 68.4% in 2023 and 73.6% in 2024.

Key products include a hyperlipidemia treatment that drove growth, and the hair-loss treatment Damocare (finasteride 1mg), which generated KRW 1.15 billion in domestic sales and KRW 350 million in exports in 2025. The customer base is mainly domestic, with supply contracts through large domestic distributors.

Overseas, the company exports 21 injectable products to 29 countries, but production capacity limits keep supply at about half of overseas demand, according to company remarks.

Competition is intensifying in generics, where marketing battles and drug price regulation are squeezing profitability, and foreign pharma entrants are adding pressure. Press analysis also points to a pipeline weighted toward generics, with few improved-new-drug approvals as of the reporting date.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩49.9B₩500M0.9%
2025Q4₩50.8B₩1.6B3.2%
2026Q1₩48B₩300M0.6%
2026Q2₩51.2B-₩800M−1.6%
2026Q3₩48.8B-₩8.3B−17.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩152.1B₩6.4B₩8B4.2%8.9%141.9%
2023₩169.6B₩1B-₩4.9B0.6%−5.8%166.5%
2024₩186.4B₩1.9B-₩3B1.0%−3.1%150.2%
2025₩195.2B₩6.8B₩1.9B3.5%1.9%160.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 152.1 billion in 2022 to KRW 169.6 billion in 2023 (up 11.5%), KRW 186.4 billion in 2024 (up 10.0%) and KRW 195.2 billion in 2025 (up 4.7%). Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022–2025 period.

Operating profit fell from KRW 6.43 billion in 2022 to KRW 964 million in 2023 (down 85.0%), then rose to KRW 1.93 billion in 2024 (up 100.1%) and KRW 6.83 billion in 2025 (up 254.4%), an increase in each of the last two years.

Operating margin was 4.2% in 2022, 0.6% in 2023, 1.0% in 2024 and 3.5% in 2025, so margins stayed thin even as sales grew and only recovered in 2025.

Press reports point to rising selling and administrative costs as the reason for the 2023 low: SG&A climbed from KRW 71.7 billion in 2022 to KRW 94.4 billion in 2023 and KRW 103.0 billion in 2024, as commission fees rose again after the company moved to a contract sales organization (CSO) model in 2020.

Net profit attributable to controlling shareholders went from KRW 7.98 billion in 2022 to a loss of KRW 4.87 billion in 2023, narrowed to a loss of KRW 3.03 billion in 2024, and turned to a profit of KRW 1.9 billion in 2025.

Total net profit including non-controlling interests was KRW 1.42 billion in 2025, a different figure from profit attributable to controlling shareholders. Operating cash flow was KRW 5.47 billion in 2022 and then -KRW 5.18 billion in 2023, -KRW 1.34 billion in 2024 and -KRW 1.7 billion in 2025.

Quarterly, operating profit peaked at KRW 1.61 billion in Q4 2025 (up 255.3% from the prior quarter), then fell to KRW 294 million in Q1 2026 (down 81.8%), turned to an operating loss of KRW 836 million in Q2 2026 and an operating loss of KRW 8.3 billion in Q3 2026.

Q3 2026 revenue was KRW 48.8 billion, down 2.1% from a year earlier, while the net loss attributable to controlling shareholders widened to KRW 11.4 billion.

A Vegan News report said Q3 2026 SG&A was KRW 36.1 billion, up 37.3% from KRW 26.3 billion a year earlier, so falling sales combined with higher SG&A deepened the loss.

05

Industry analysis

Myungmoon Pharm's position is that of a domestic business centered on generics. The wisereport company monitor describes profitability in generics as squeezed by marketing competition and drug price regulation, with competition intensifying as foreign companies enter the market.

Drug price policy has hit earnings directly before: according to The Bio News, a unified drug price cut introduced in 2012 led to a year-on-year revenue decline. The 2020 move to a CSO model eased personnel costs, but rising commission fees later pushed SG&A higher, a structural issue that persisted.

In overseas markets, injectables are the differentiating axis. The company exports 21 injectable products to 29 countries but supplies only about half of overseas demand because of capacity limits. EU GMP certification is seen as the gateway to demanding European markets.

Compared with listed peers in the same sector that are widening growth through new drugs or contract manufacturing, Myungmoon Pharm has a relatively large share of generics and domestic sales.

The cycle position is a return to operating losses in 2026, and whether this is a recovery phase or a period of greater uncertainty will depend on the next quarters' SG&A trend and the pace of sales recovery.

06

Outlook

In December 2025 the company said it expects Damocare sales of about KRW 3.5 billion in 2026. A supply contract worth KRW 2.5 billion with a domestic distribution partner was reported as already completed.

In Japan, an order of about USD 300,000 is expected for 2026, and supply of 10 batches is described as confirmed, according to company statements. Depending on negotiations, supply could expand to 15 to 20 batches.

For injectables, a production facility upgrade project of roughly KRW 20 billion received government support, as reported on April 23, 2026. The company has set a goal of gradually expanding injectable exports to about KRW 10 billion, with securing EU GMP certification cited as the key variable.

A 2025 report on the third-quarter cumulative results said the company was pursuing the sale of a non-core golf club asset, The Durban Golf Club, and management said it would focus more on R&D if the sale goes through.

Cumulative interest coverage for the first nine months of 2025 was reported above 1, but operating losses since the second quarter of 2026 mean its ability to cover interest from operating profit needs to be verified again.

The next checkpoint is the scale of Damocare sales and progress on injectable capacity investment disclosed in the 2026 annual report.

07

Valuation

PER
—
PBR
0.4×
ROE
-13.7%
EPS
-₩373
BPS
₩2,565
Dividend per share
₩0

Because the net loss over the last four quarters means the price-to-earnings ratio cannot be calculated, valuation has to be read from other angles. The price-to-book ratio sits well below 1x, meaning the stock trades at a low price relative to book net assets.

However, controlling-shareholder equity was KRW 98.7 billion at the end of 2025 and the debt ratio was 160.8%, so the meaning of a discount to book value depends on the debt burden.

Per a Daily Pharm report, short-term borrowings were KRW 54.3 billion at the end of the third quarter of 2025, or 56.98% of total borrowings of KRW 95.3 billion. The dividend yield is close to zero, so shareholder return is a limited factor in the valuation.

Even after the 2025 return to profit, the P/E has moved between loss and profit periods, which makes past multiples a poor benchmark band. Because P/B reflects both the share price and controlling-shareholder equity, continued losses that shrink that equity base also need to be tracked.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Three years of revenue growth and profit recovery

Revenue rose for three consecutive years from 2023 through 2025 to KRW 195.2 billion. Operating profit reached KRW 6.83 billion in 2025, up 254.4%, and operating margin recovered to 3.5%.

Profit attributable to controlling shareholders returned to a KRW 1.9 billion profit, and Q4 2025 operating profit of KRW 1.61 billion showed improvement at the quarterly level.

Injectable capacity expansion and EU GMP

The company exports 21 injectable products to 29 countries but supplies only about half of overseas demand due to capacity limits. A production upgrade of roughly KRW 20 billion, backed by a government-selected program, is presented as the means to close that gap. The company describes shifting its export mix toward higher-value markets on the basis of EU GMP certification.

Damocare growth and Japan export expansion

Damocare generated KRW 1.15 billion in domestic sales and KRW 350 million in exports in 2025, totaling KRW 1.5 billion. The company expects about KRW 3.5 billion in sales for 2026 and has described 10 batches of Japan supply as confirmed. The projection comes from company statements rather than independently verified figures.

09

Bear factors

Return to operating losses in 2026

Operating losses were KRW 836 million in Q2 2026 and KRW 8.3 billion in Q3 2026, two consecutive quarters in the red. The Q3 2026 net loss attributable to controlling shareholders widened to KRW 11.4 billion, and the four-quarter total is KRW 12.6 billion. The Q4 2025 profit did not carry into subsequent quarters.

SG&A burden and falling sales

SG&A rose from KRW 71.7 billion in 2022 to KRW 103.0 billion in 2024, and a Vegan News report said Q3 2026 SG&A rose 37.3% from a year earlier. Revenue in the same quarter fell 2.1% from a year earlier, so falling sales and higher SG&A coincided. With thin operating margins, rising SG&A widens swings in profit and loss.

Balance sheet and cash flow

The debt ratio was 160.8% at the end of 2025 and total liabilities were KRW 168 billion. Operating cash flow has been negative since 2023, and short-term borrowings exceeded half of total borrowings at the end of Q3 2025.

The interest coverage above 1 reflects cumulative results through Q3 2025, so it needs to be rechecked against the 2026 operating losses.

10

Risk factors

Drug pricing and generic competition

Generics are exposed to drug price regulation and marketing competition, so price cuts or higher promotion costs could weigh on operating margin. Entry by foreign companies intensifies domestic share competition. A shift in prescribing for key products would feed directly into revenue.

Financing and interest burden

With a debt ratio of 160.8% and a high share of short-term borrowings, the company is exposed to interest rates and refinancing terms. Interest coverage was above 1 through Q3 2025, but during operating losses that ratio could fall below 1 again. Because a non-core asset sale is tied to debt repayment, the pace of that sale is also a risk factor.

Overseas certification and capacity execution

The injectable expansion is a project of roughly KRW 20 billion, so construction, completion and EU GMP certification timing could slip. Any delay would push back the target of about KRW 10 billion in injectable exports.

Press criticism of a generics-heavy R&D pipeline suggests the pace of export diversification through new products may also be limited.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will show full-year operating results, the SG&A structure and whether Damocare sales reached the company's target of about KRW 3.5 billion. The sign of full-year operating profit will confirm the trajectory of Q4 2026.

  2. Mid-May 2027 (Q1 2027 quarterly report deadline)

    Whether Q1 2027 operating results move out of the red, and whether SG&A growth outpaces revenue growth. If both improve together, that would indicate the causes of the 2026 losses are easing.

  3. First half of 2027 (date not yet announced)

    Completion of the injectable facility upgrade and whether EU GMP certification is obtained. Certification would indicate progress toward the export expansion target.

  4. Date not yet announced

    Whether the non-core golf club sale is completed and how much of the proceeds go to repaying borrowings. The repayment scale connects directly to interest burden and the debt ratio.

12

Overall view

Myungmoon Pharm grew revenue for three consecutive years through 2025 and recovered operating profit and profit attributable to controlling shareholders, so improvement in both sales and earnings is visible in the filed numbers.

However, operating losses have continued since Q2 2026, with a Q3 2026 operating loss of KRW 8.3 billion and a four-quarter controlling-shareholder net loss total of KRW 12.6 billion.

Strengths include Damocare's growth target, the capacity expansion aimed at easing the injectable export constraint, and a price-to-book ratio well below 1x. Weaknesses include rising SG&A, a generics-centered competitive structure, a 160.8% debt ratio and negative operating cash flow.

These factors should be weighed equally, and which side prevails will become clearer from the full-year operating results and SG&A structure in the 2026 annual report. No public schedule has been announced for the injectable facility upgrade or EU GMP certification, so their execution needs to be checked later. This report is provided for information only and does not include a buy or sell opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. dailypharm.com
  3. medipana.com
  4. vegannews.co.kr
  5. comp.fnguide.com
  6. kmedinfo.co.kr
  7. medisobizanews.com
  8. thebionews.net
  9. whosaeng.com
  10. thebionews.net
  11. bosa.co.kr
  12. dailypharm.com
  13. whosaeng.com
  14. medipharmhealth.co.kr
  15. jobkorea.co.kr
  16. pflow.keywordegg.com
  17. news.dealsitetv.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis